GlobeImmune, Inc. (GBIM)

GlobeImmune, Inc. (GBIM) Healthcare & Pipeline Overview

GlobeImmune, Inc. is a biopharmaceutical company leveraging its proprietary Tarmogen platform to develop therapeutic products for cancer and infectious diseases. Headquartered in Louisville, Colorado, the company is advancing multiple candidates, including GS-4774 for hepatitis B and GI-4000 for various cancers, through clinical trials, supported by strategic collaborations.

What Is the Investment Thesis for GBIM?

GlobeImmune, Inc. presents a research-stage investment profile centered on its proprietary Tarmogen platform and a diverse pipeline targeting oncology and infectious diseases. The company's value drivers include the potential clinical success of its lead candidates, such as GS-4774 for hepatitis B and GI-4000 for various cancers, which are currently in Phase 2 and Phase 2b trials. Strategic collaborations with Gilead Sciences and Celgene Corporation provide external validation and potential pathways for advanced development and commercialization, mitigating some of the R&D burden for a company with only two employees. The breadth of its pipeline, spanning multiple therapeutic areas from chronic viral infections to various solid tumors, offers multiple shots on goal. However, the company's current market capitalization of 575 and a profit margin of -42.8% reflect its early-stage, development-heavy nature and lack of commercialized products. The highly negative Beta of -200.46 indicates extreme historical volatility and an inverse relationship to broader market movements, suggesting significant speculative risk. Future catalysts are heavily reliant on positive clinical trial outcomes and the progression of its pipeline through regulatory milestones.

Based on FMP financials and quantitative analysis

GBIM Key Highlights

• GlobeImmune, Inc. operates with a lean structure, employing only 2 individuals, indicating a highly focused R&D model reliant on external collaborations.
• The company maintains a gross margin of 59.0%, which is notable for a biopharmaceutical company, despite a negative profit margin of -42.8% due to significant R&D expenditures.
• GlobeImmune's market capitalization is reported as $0.00B, reflecting a very low valuation typical of companies in early-stage development with no commercialized products.
• The company's Beta is an extreme -200.46, suggesting an exceptionally high degree of inverse volatility relative to the broader market, which is highly unusual for any publicly traded entity.
• GlobeImmune has established strategic collaborations with major pharmaceutical companies, Gilead Sciences, Inc. and Celgene Corporation, for the development of its therapeutic candidates.

Who Are GBIM's Competitors?

GBIM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GBIM's Key Strengths?

• Proprietary Tarmogen platform with potential for diverse therapeutic applications.
• Pipeline includes multiple candidates in Phase 2/2b clinical trials for significant diseases.
• Strategic collaborations with major pharmaceutical companies (Gilead, Celgene).
• Focus on high-unmet-need areas like chronic hepatitis B and various cancers.

What Are GBIM's Weaknesses?

• Extremely small operational team of 2 employees.
• Negative profit margin and reported 575 market capitalization, indicating limited financial resources.
• Reliance on successful clinical trial outcomes, which are inherently uncertain.
• No commercialized products or revenue streams from product sales yet.

What Could Drive GBIM Stock Higher?

• Positive data readout from Phase 2 trials for GS-4774 in chronic hepatitis B virus infection.
• Advancement of GI-4000 from Phase 2b to Phase 3 trials for resected pancreas cancer.
• Initiation of new clinical trials for preclinical infectious disease candidates (GI-19000, GI-2010, GI-18000).
• Continued progress and achievement of development milestones under strategic collaborations with Gilead Sciences and Celgene Corporation.
• Positive clinical updates or data presentations for GI-6301 in brachyury-expressing cancers or GI-6207 in medullary thyroid cancer.

What Are the Key Risks for GBIM?

• Financial-distress signal — its Altman Z-Score of -31.84 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-64.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• High clinical trial failure rates inherent in biopharmaceutical development, particularly for early-stage companies.
• Significant capital requirements for R&D, potentially leading to further dilution or financial distress given the current market capitalization.
• Intense competition from larger, better-funded pharmaceutical and biotechnology companies with similar or more advanced therapies.
• Reliance on strategic partners (Gilead, Celgene) for funding, expertise, and commercialization, with potential for partnership termination or unfavorable terms.
• Regulatory risks and lengthy approval processes, which can delay or prevent market entry for product candidates.
• Liquidity challenges and extreme volatility associated with trading on the 'OTC Other' market, coupled with unknown disclosure status.

What Are the Growth Opportunities for GBIM?

• **Advancement of GS-4774 for Hepatitis B:** The global market for hepatitis B treatment is substantial, driven by millions of chronic carriers worldwide. GS-4774, currently in Phase 2 trials, represents a significant growth opportunity if it demonstrates efficacy and safety. Successful progression through clinical development and regulatory approval could address a persistent unmet medical need for improved hepatitis B therapies, potentially offering a functional cure or better long-term management. The market for chronic hepatitis B treatments is projected to reach several billion dollars annually, with innovative immunotherapies like Tarmogens having the potential to capture a meaningful share by offering differentiated mechanisms of action.
• **Development of GI-6301 for Brachyury-Expressing Cancers:** GI-6301 targets cancers that express the brachyury protein, a potential novel target for various solid tumors. This approach opens a growth avenue in oncology, particularly for cancers where brachyury is overexpressed and current treatments are limited. The market for targeted cancer therapies continues to expand, with significant investment in precision medicine. Identifying and successfully developing therapies for specific protein targets like brachyury could unlock access to niche but high-value patient populations, offering a competitive advantage in a crowded oncology landscape. The timeline for this opportunity depends on successful Phase 2 and subsequent pivotal trials.
• **Progress of GI-4000 for Multiple Cancers:** GI-4000 is being evaluated in Phase 2b clinical trials for resected pancreas cancer and Phase 2 trials for non-small cell lung cancer (NSCLC) and colorectal cancer. These are among the most prevalent and challenging cancers globally, representing multi-billion dollar markets. Success in any of these indications would provide substantial growth. Pancreatic cancer, in particular, has a high unmet need for effective treatments. The ability to target multiple indications with a single platform technology like Tarmogen for GI-4000 demonstrates pipeline efficiency and broad market potential, with each successful trial potentially leading to significant value creation over the next 3-7 years.
• **Expansion of Preclinical Infectious Disease Pipeline:** GlobeImmune's preclinical pipeline includes candidates like GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus infection. These represent vast global health challenges with significant market sizes, particularly in developing regions. While in early stages, successful preclinical development and subsequent entry into clinical trials could unlock substantial long-term growth opportunities. The demand for novel treatments for these infectious diseases remains high, driven by drug resistance, limited efficacy of existing therapies, and global disease burden. This diversification into infectious diseases complements its oncology focus and broadens its potential market reach over a longer-term horizon (5-10+ years).
• **Leveraging Strategic Collaborations with Gilead and Celgene:** GlobeImmune's strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation are critical growth drivers. These partnerships provide access to significant financial resources, advanced research capabilities, and extensive global commercialization networks that a small biopharmaceutical company with two employees would otherwise lack. These collaborations not only validate GlobeImmune's Tarmogen platform but also accelerate the development and potential market entry of its product candidates. Successful progression of partnered programs could lead to milestone payments, royalties, and shared development costs, providing stable funding and reducing the financial burden on GlobeImmune, thereby fueling further pipeline innovation and expansion.

What Opportunities Does GBIM Have?

• Successful advancement of lead candidates (e.g., GS-4774, GI-4000) through pivotal trials and regulatory approval.
• Expansion of the Tarmogen platform into new therapeutic areas or indications.
• Potential for significant milestone payments and royalties from existing or new collaborations.
• Addressing large, underserved markets in oncology and infectious diseases with novel immunotherapies.

What Threats Does GBIM Face?

• High failure rate of drug candidates in clinical trials.
• Intense competition from larger pharmaceutical companies and other biotech firms.
• Regulatory hurdles and lengthy approval processes for new drugs.
• Dependence on partners for funding and commercialization, with potential for partnership termination.
• Market perception and liquidity challenges associated with OTC trading and extremely low market capitalization.

What Are GBIM's Competitive Advantages?

• **Proprietary Tarmogen Platform:** The company's core Tarmogen platform represents a unique technological approach to stimulating T-cell immune responses, potentially offering differentiated therapeutic mechanisms.
• **Diverse Clinical Pipeline:** A broad pipeline spanning multiple oncology indications and infectious diseases provides multiple opportunities for clinical success and market penetration.
• **Strategic Collaborations:** Partnerships with established pharmaceutical companies like Gilead Sciences and Celgene Corporation provide access to significant resources, expertise, and market reach, which are difficult for small biotechs to replicate independently.
• **Intellectual Property:** Patents surrounding the Tarmogen platform and specific product candidates offer a degree of protection against direct competition.
• **Specialized Expertise:** A highly focused team, albeit small, with specialized knowledge in immunology and biopharmaceutical development, is critical for advancing complex therapeutic programs.

What Does GBIM Do?

GlobeImmune, Inc., founded in 1995 and headquartered in Louisville, Colorado, is a biopharmaceutical company dedicated to the discovery and development of therapeutic products for oncology and infectious diseases. The company's core technological foundation is its proprietary Tarmogen platform, which is designed to stimulate specific T-cell immune responses. Initially incorporated as Ceres Pharmaceuticals, Inc., the company rebranded to GlobeImmune, Inc. in May 2001, signaling its focused shift towards immunotherapeutic development. GlobeImmune's pipeline features several product candidates in various stages of clinical development. Notably, GS-4774 is currently in Phase 2 trials for patients chronically infected with hepatitis B virus, including those on oral antiviral suppressive therapy. In the oncology space, GI-6301 is being developed for cancers expressing the brachyury protein, while GI-6207 is in Phase 2 clinical trials targeting medullary thyroid cancer. A significant part of its oncology efforts involves GI-4000, which is in Phase 2b clinical trials for resected pancreas cancer and also in Phase 2 clinical trials for non-small cell lung cancer and colorectal cancer. Beyond these advanced programs, GlobeImmune maintains a preclinical pipeline addressing infectious diseases, including GI-19000 for tuberculosis, GI-2010 for human immunodeficiency virus (HIV), and GI-18000 for hepatitis D virus infection. The company has established strategic collaborations with prominent pharmaceutical firms, including Gilead Sciences, Inc. and Celgene Corporation, which are crucial for the development and potential commercialization of its product candidates. With a lean operational structure, the company employs two individuals, underscoring its focus on research and development through partnerships.

What Products and Services Does GBIM Offer?

• Develops therapeutic products for cancer and infectious diseases.
• Utilizes a proprietary Tarmogen platform to stimulate specific T-cell immune responses.
• Conducts Phase 2 trials for GS-4774, targeting chronic hepatitis B virus infection.
• Advances GI-6301 for cancers expressing the brachyury protein.
• Manages Phase 2 clinical trials for GI-6207 to treat medullary thyroid cancer.
• Progresses GI-4000 through Phase 2b trials for resected pancreas cancer and Phase 2 for non-small cell lung cancer and colorectal cancer.
• Maintains a preclinical pipeline for infectious diseases, including tuberculosis, HIV, and hepatitis D virus.
• Engages in strategic collaborations with major pharmaceutical companies like Gilead Sciences, Inc. and Celgene Corporation.

How Does GBIM Make Money?

• Primarily generates revenue through research and development activities, potentially including milestone payments from strategic collaborations.
• Relies on its proprietary Tarmogen platform to create novel immunotherapies for various diseases.
• Aims to develop and advance product candidates through clinical trials, seeking regulatory approval for commercialization.
• Partners with larger pharmaceutical companies for funding, expertise, and potential commercialization of its drug candidates.
• Focuses on intellectual property protection for its Tarmogen platform and pipeline assets.

What Industry Does GBIM Operate In?

GlobeImmune, Inc. operates within the highly specialized and capital-intensive Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by long development cycles, high regulatory hurdles, and significant R&D expenditures, with success heavily dependent on clinical trial outcomes. The broader healthcare market is experiencing trends such as increasing demand for novel therapies for chronic diseases, a growing focus on personalized medicine, and the emergence of advanced immunotherapies. GlobeImmune's Tarmogen platform positions it within the immunotherapy segment, a rapidly evolving area with substantial market potential for both cancer and infectious diseases. The competitive landscape is intense, featuring numerous large pharmaceutical companies and smaller biotech firms vying for market share with innovative drug candidates. GlobeImmune's strategy of developing a diverse pipeline and leveraging strategic partnerships is common in this industry to de-risk development and access broader resources. The company's current stage with multiple Phase 2 programs places it in a critical phase of development, where significant value inflection points can occur.

Who Are GBIM's Key Customers?

• Ultimately targets patients suffering from chronic hepatitis B, various cancers (pancreas, medullary thyroid, NSCLC, colorectal), tuberculosis, HIV, and hepatitis D.
• Pharmaceutical partners, such as Gilead Sciences, Inc. and Celgene Corporation, are key collaborators and potential licensees.
• Healthcare providers and medical institutions would be the prescribers and administrators of any approved therapies.
• Regulatory bodies (e.g., FDA) are critical stakeholders for product approval.

Net sellingInsider Activity

The most recent 12 insider filings for GlobeImmune, Inc. break down as 12 sales and 0 purchases. On net that is roughly 162K shares disposed (about $342K), a signal worth weighing alongside the fundamentals.

GBIM Valuation & Market Position

With a 575 market cap, GlobeImmune, Inc. sits in the micro-cap segment of the market. Relative to its peer group, GBIM's quantitative score of 53/100 is below the peer average of 76/100.

ROE -64%Key Financial Metrics

Return on equity for GlobeImmune, Inc. stands at -64.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -24.0%, showing how much profit it generates from its asset base. A current ratio of 2.62 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 2/9Financial Health

GlobeImmune, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -31.84 places it in the distress zone, a signal of elevated financial risk.

Company Profile

GlobeImmune, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Louisville, US. The company is led by CEO Donald Bellgrau. GBIM has traded publicly since 2014.

GBIM Financials

GBIM Latest News

No recent news available for GBIM.

GBIM Analyst Consensus

GBIM MoonshotScore

What Investors Ask About GlobeImmune, Inc. (GBIM) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources